ArriVent BioPharma, Inc.
AVBP
$34.00
$0.180.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -43.32M | -35.96M | -34.75M | -31.21M | -64.39M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.93M | 615.00K | 3.49M | 3.12M | 2.27M |
| Change in Net Operating Assets | -3.50M | 4.69M | -4.54M | 1.96M | -5.89M |
| Cash from Operations | -41.89M | -30.66M | -35.80M | -26.12M | -68.01M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.58M | -71.20M | -50.76M | 13.91M | 36.82M |
| Cash from Investing | 3.58M | -71.20M | -50.76M | 13.91M | 36.82M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 54.87M | 34.74M | 86.17M | 75.42M | 6.81M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -17.00K | 300.00K | -303.00K | -50.00K |
| Cash from Financing | 54.87M | 34.73M | 86.47M | 75.11M | 6.76M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16.56M | -67.13M | -93.00K | 62.90M | -24.43M |